6-bromo-3-[(E)-3-(3-nitrophenyl)prop-2-enoyl]-4-phenyl-1H-quinolin-2-one | 5509-44-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-bromo-3-[(E)-3-(3-nitrophenyl)prop-2-enoyl]-4-phenyl-1H-quinolin-2-one
• CAS: 5509-44-4
• 化学式: C24H15BrN2O4
• 分子量: 475.3
• InChiKey: QBWLWXHTEDANPQ-FMIVXFBMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  92
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Substituted4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof
  申请人：Cai Xiong Sui

  公开号：US20050165053A1

  公开（公告）日：2005-07-28

  The present invention is directed to substituted 4-Aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1H)-quinolinones and analogs thereof, represented by the general Formula I: wherein Ar 1 , Ar 2 , R 1 -R 6 and R 12 are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. The compounds of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明涉及替代的4-芳基-3-(3-芳基-1-氧代-2-丙烯基)-2(1H)-喹啉酮及其类似物，由通式I所表示，其中Ar1，Ar2，R1-R6和R12在此被定义。本发明还涉及发现具有式I的化合物是caspase的激活剂和凋亡诱导剂。本发明的化合物可用于在许多临床情况下诱导细胞死亡，其中存在异常细胞的不受控制的生长和扩散。
• Heteroaryl inhibitors of PAD4
  申请人：PADLOCK THERAPEUTICS, INC.

  公开号：US11026937B2

  公开（公告）日：2021-06-08

  The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

  本发明提供了可用作 PAD4 抑制剂的化合物、其组合物以及治疗 PAD4 相关疾病的方法。
• SUBSTITUTED 4-ARYL-3-(3-ARYL-1-OXO-2-PROPENYL)-2(1H)-QUINOLINONES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF
  申请人：Cytovia, Inc.

  公开号：EP1404329A1

  公开（公告）日：2004-04-07
• EP1404329A4
  申请人：——

  公开号：EP1404329A4

  公开（公告）日：2006-11-02
• METHODS OF IDENTIFYING AND TREATING IMMUNE CHECKPOINT INHIBITOR-RESPONSIVE NEOPLASMS AND CELLS, TRANSGENIC ANIMALS AND KITS FOR USE THEREIN
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US20190085404A1

  公开（公告）日：2019-03-21

  Provided are methods of identifying whether a subject having cancer will be responsive to agents that combat immune evasion, such as immune checkpoint inhibitors. Methods of treating a subject having cancer are also provided. Such methods may include those that involve identifying whether the cancer will be responsive to an immune checkpoint inhibitor and/or is an immune-evasive cancer and administering an agent, e.g., an immune checkpoint inhibitor and/or a MYC inhibitor, to the subject to treat the cancer. Also provided are methods of identifying cancer therapeutics that are effective during MYC-regulated immune evasion as well as cancer cell lines and transgenic animals useful in such methods. Kits for use in the described methods are also provided.